Amphastar Pharmaceuticals
AMPH
211 hedge funds and large institutions have $764M invested in Amphastar Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 70 increasing their positions, 82 reducing their positions, and 15 closing their positions.
325% more call options, than puts
Call options by funds: $1.34M | Put options by funds: $316K
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
3% more funds holding
Funds holding: 205 → 211 (+6)
4.45% less ownership
Funds ownership: 60.89% → 56.44% (-4.4%)
9% less capital invested
Capital invested by funds: $839M → $764M (-$74.9M)
15% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 82
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$6.71M |
| 2 |
Goldman Sachs
New York
|
+$2.7M |
| 3 |
Millennium Management
New York
|
+$2.43M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.89M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$6.25M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.09M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.85M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$3.37M |
| 5 |
BlackRock
New York
|
-$3.17M |
AMPH Hedge Fund Activity: Q4 2022 in Review
211 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q4 2022, worth a combined $764M — down 8.9% from $839M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AMPH positions and 15 closed out — a net gain of 11 holders — while 70 added to existing stakes and 82 trimmed.
The largest buyer was Pacer Advisors, opening a new position worth an estimated $6.71M. The largest seller was Fuller & Thaler Asset Management, cutting an estimated $6.25M.
- 211 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q4 2022, up from 205 in Q3 2022.
- Funds reported $764M of Amphastar Pharmaceuticals stock for Q4 2022, down 8.9% quarter-over-quarter.
- 26 funds opened new Amphastar Pharmaceuticals positions in Q4 2022 and 15 closed out, a net change of +11 holders.
- The largest Amphastar Pharmaceuticals buyer in Q4 2022 was Pacer Advisors, an estimated $6.71M added.
- The largest Amphastar Pharmaceuticals seller in Q4 2022 was Fuller & Thaler Asset Management, an estimated $6.25M sold.
Based on aggregated 13F filings for Q4 2022.